No Data
REGENXBIO to Host Conference Call on March 13 to Discuss Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Highlights
REGENXBIO to Participate in Upcoming Investor Conferences
Leerink Partners Sticks to Their Buy Rating for RegenXBio (RGNX)
Analysts Have Conflicting Sentiments on These Healthcare Companies: Adaptive Biotechnologies (ADPT), RegenXBio (RGNX) and Ramsay Health Care (OtherRMSYF)
Regenxbio's Gene Therapy Outlook Dims As Rival Treatments Gain Ground, Goldman Sachs Warns
A Glimpse Into The Expert Outlook On Regenxbio Through 7 Analysts
HUANG AI : thanks for sharing
magickbeans710 : Thanks man
103567231 : Bro. I saw your post, noticed those colorful ones, but they have already started to skyrocket. I dare not buy. How did you get this information? We are all too late to Buy. Thank you.
Jaguar8 OP 103567231 : Whoever is telling you to buy anyway? It’s your decision and it’s MY WATCHLIST.
Jaguar8 OP 103567231 : Unfollow me and make your own watchlist.
View more comments...